{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:41Z","timestamp":1785510521015,"version":"3.56.0"},"reference-count":32,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    In high income settings, insulin analogues were associated with improved glycemic control among adults with diabetes, mainly measured through HbA1c and hypoglycemic episodes. In low- and middle-income countries, especially those affected by humanitarian crises, analogue insulins may be helpful as proper diabetes care for this population remains challenging; yet, supporting evidence is lacking.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Routinely collected continuous glucose sensor data from patients with Type 1 diabetes, aged 4 to 18\u00a0years old, between April 2019 and December 2022 was retrospectively extracted. Changes in glycemic metrics while using analogue insulins were compared with human insulin using multiple linear regression with random effects.\n                    <jats:bold>Results:<\/jats:bold>\n                    Forty-five patients included in the study used continuous glucose monitor devices for an average duration of 73\u00a0days (\u00b153) while using human insulin and 170\u00a0days (\u00b183) while using analogue insulins. Compared with human insulin, analogue insulins were associated with an additional 26\u00a0min (95% CI; 15, 37, p\u00a0&lt;\u00a00.001) per day spent within the normal target range and a reduction of 11\u00a0min (95% CI; -16, -5) and 10\u00a0min (95% CI; -13, -7) in overall and nocturnal hypoglycemia, respectively. Analogue insulin was also associated with a reduction of 6\u00a0mg\/dl in 24\u00a0h mean glucose.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Insulin analogues were associated with slight improvements in time within and below range compared with human insulin, yet within patient glycemic variability remains high. Further research is needed to explore its acceptability among patients, impact on quality of life and its cost-effectiveness and sustainability in low resource contexts.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0036","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:46:38Z","timestamp":1784202398000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world comparative effectiveness of analogue and human insulin on glycemic control in children and adolescents with Type 1 diabetes in Lebanon using continuous glucose monitoring data"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9820-5124","authenticated-orcid":false,"given":"Sahar","family":"Masri","sequence":"first","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Albela","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iza","family":"Ciglenecki","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Boulle","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Hachem","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sola","family":"Bahous","sequence":"additional","affiliation":[{"name":"Lebanese American University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Prieto-Merino","sequence":"additional","affiliation":[{"name":"University of Alcal\u00e1, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Perel","sequence":"additional","affiliation":[{"name":"London School of Hygiene &amp; Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"2","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi I","year":"2026","unstructured":"Genitsaridi I, Salpea P, Salim A 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol. 14(2), 149\u2013156 (2026).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"112277","DOI":"10.1016\/j.diabres.2025.112277","article-title":"Global Type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International Diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0","volume":"225","author":"Ogle GD","year":"2025","unstructured":"Ogle GD, Wang F, Haynes A Global Type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International Diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res. Clin. Pract. 225, 112277 (2025).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"107842","DOI":"10.1016\/j.diabres.2019.107842","article-title":"Worldwide estimates of incidence, prevalence and mortality of Type 1 diabetes in children and adolescents: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Patterson CC","year":"2019","unstructured":"Patterson CC, Karuranga S, Salpea P Worldwide estimates of incidence, prevalence and mortality of Type 1 diabetes in children and adolescents: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 157, 107842 (2019).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"e_1_3_10_6_2","volume-title":"Refugee Data Finder","author":"United Nations High Commissioner for Refugees","year":"2026","unstructured":"United Nations High Commissioner for Refugees. Refugee Data Finder. UNHCR, Geneva, Switzerland (20 May 2026). Available from: https:\/\/www.unhcr.org\/refugee-statistics"},{"issue":"8","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S2213-8587(19)30082-8","article-title":"The burden of diabetes and use of diabetes care in humanitarian crises in low-income and middle-income countries","volume":"7","author":"Kehlenbrink S","year":"2019","unstructured":"Kehlenbrink S, Smith J, Ansbro \u00c9 The burden of diabetes and use of diabetes care in humanitarian crises in low-income and middle-income countries. Lancet Diabetes Endocrinol. 7(8), 638\u2013647 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10313","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(21)02247-9","article-title":"A century past the discovery of insulin: global progress and challenges for Type 1 diabetes among children and adolescents in low-income and middle-income countries","volume":"398","author":"Bhutta ZA","year":"2021","unstructured":"Bhutta ZA, Salam RA, Gomber A A century past the discovery of insulin: global progress and challenges for Type 1 diabetes among children and adolescents in low-income and middle-income countries. Lancet 398(10313), 1837\u20131850 (2021).","journal-title":"Lancet"},{"issue":"3","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/1947-2714.153918","article-title":"Clinical use of insulin degludec: practical experience and pragmatic suggestions","volume":"7","author":"Kalra S","year":"2015","unstructured":"Kalra S, Gupta Y. Clinical use of insulin degludec: practical experience and pragmatic suggestions. N. Am. J. Med. Sci. 7(3), 81\u201385 (2015).","journal-title":"N. Am. J. Med. Sci."},{"key":"e_1_3_10_10_2","volume-title":"Endotext","author":"Donnor T","year":"2000","unstructured":"Donnor T, Sarkar S. Insulin \u2013 pharmacology, therapeutic regimens and principles of intensive insulin therapy. In: Endotext. Feingold KR, Adler RA, Ahmed SF (Eds). MDText.com, Inc., MA, USA (2000)."},{"issue":"4","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.diabet.2016.03.001","article-title":"Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with Type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial","volume":"42","author":"Agesen RM","year":"2016","unstructured":"Agesen RM, Kristensen PL, Beck-Nielsen H Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with Type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial. Diabetes Metab. 42(4), 249\u2013255 (2016).","journal-title":"Diabetes Metab."},{"issue":"1","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12902-016-0146-2","article-title":"A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with Type 1 diabetes mellitus","volume":"16","author":"Liu M","year":"2016","unstructured":"Liu M, Zhou Z, Yan J A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with Type 1 diabetes mellitus. BMC Endocr. Disord. 16(1), 67 (2016).","journal-title":"BMC Endocr. Disord."},{"issue":"3","key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2337\/diacare.26.3.799","article-title":"Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with Type 1 diabetes on intensive insulin regimens","volume":"26","author":"Murphy NP","year":"2003","unstructured":"Murphy NP, Keane SM, Ong KK Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with Type 1 diabetes on intensive insulin regimens. Diabetes Care 26(3), 799\u2013804 (2003).","journal-title":"Diabetes Care"},{"key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.clinthera.2007.12.014","article-title":"Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus","volume":"29","author":"Danne T","year":"2007","unstructured":"Danne T. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin. Ther. 29(Suppl. D), S145\u2013S152 (2007).","journal-title":"Clin. Ther."},{"issue":"2","key":"e_1_3_10_15_2","first-page":"164","article-title":"Hypoglycemia frequency and treatment satisfaction in patients receiving insulin analogues for treatment of Type 1 diabetes mellitus","volume":"65","author":"Berlanda G","year":"2021","unstructured":"Berlanda G, Telo GH, Krug BC Hypoglycemia frequency and treatment satisfaction in patients receiving insulin analogues for treatment of Type 1 diabetes mellitus. Arch. Endocrinol. Metab. 65(2), 164\u2013171 (2021).","journal-title":"Arch. Endocrinol. Metab."},{"issue":"4","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/pdi.2345","article-title":"Access to insulin: a comparison between low- and middle-income countries and the United Kingdom","volume":"38","author":"Lepeska M","year":"2021","unstructured":"Lepeska M, Beran D, Ewen M. Access to insulin: a comparison between low- and middle-income countries and the United Kingdom. Practical Diabetes 38(4), 13\u201316 (2021).","journal-title":"Practical Diabetes"},{"issue":"9","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"e3553","DOI":"10.1210\/clinem\/dgac331","article-title":"Strengthening diabetes care in humanitarian crises in low- and middle-income settings","volume":"107","author":"Kehlenbrink S","year":"2022","unstructured":"Kehlenbrink S, Ansbro \u00c9, Besan\u00e7on S, Hassan S, Roberts B, Jobanputra K. Strengthening diabetes care in humanitarian crises in low- and middle-income settings. J. Clin. Endocrinol. Metab. 107(9), e3553\u2013e3561 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"e_1_3_10_18_2","first-page":"S16","article-title":"Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters","volume":"19","author":"Wright LA","year":"2017","unstructured":"Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol. Ther. 19(Suppl. 2), S16\u2013S26 (2017).","journal-title":"Diabetes Technol. Ther."},{"issue":"1","key":"e_1_3_10_19_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13031-019-0191-3","article-title":"Treating Syrian refugees with diabetes and hypertension in Shatila refugee camp, Lebanon: M\u00e9decins Sans Fronti\u00e8res model of care and treatment outcomes","volume":"13","author":"Kayali M","year":"2019","unstructured":"Kayali M, Moussally K, Lakis C Treating Syrian refugees with diabetes and hypertension in Shatila refugee camp, Lebanon: M\u00e9decins Sans Fronti\u00e8res model of care and treatment outcomes. Conflict Health 13(1), 12 (2019).","journal-title":"Conflict Health"},{"key":"e_1_3_10_20_2","doi-asserted-by":"crossref","first-page":"109807","DOI":"10.1016\/j.diabres.2022.109807","article-title":"Children with type one diabetes who are migrants and refugees suffer from poor metabolic control and frequent acute complications, a study from Jordan, a limited resource country with high migrant\/refugee population","volume":"185","author":"Odeh R","year":"2022","unstructured":"Odeh R, Gharaibeh L, Badran EF, Bani Hani F, Alassaf A. Children with type one diabetes who are migrants and refugees suffer from poor metabolic control and frequent acute complications, a study from Jordan, a limited resource country with high migrant\/refugee population. Diabetes Res. Clin. Pract. 185, 109807 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"01","key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4236\/jdm.2015.51002","article-title":"Clinical audit on the provision of diabetes care in the primary care setting by United nations relief and works agency for Palestine refugees in the near East (UNRWA)","volume":"5","author":"Shahin Y","year":"2014","unstructured":"Shahin Y, Kapur A, Khader A Clinical audit on the provision of diabetes care in the primary care setting by United nations relief and works agency for Palestine refugees in the near East (UNRWA). J. Diabetes Mellitus 5(01), 12 (2014).","journal-title":"J. Diabetes Mellitus"},{"issue":"8","key":"e_1_3_10_22_2","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino T","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42(8), 1593\u20131603 (2019).","journal-title":"Diabetes Care"},{"issue":"3","key":"e_1_3_10_23_2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck RW","year":"2019","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 42(3), 400\u2013405 (2019).","journal-title":"Diabetes Care"},{"issue":"3","key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s13300-019-0619-1","article-title":"A view beyond HbA1c: role of continuous glucose monitoring","volume":"10","author":"Chehregosha H","year":"2019","unstructured":"Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F. A view beyond HbA1c: role of continuous glucose monitoring. Diabetes Ther. 10(3), 853\u2013863 (2019).","journal-title":"Diabetes Ther."},{"issue":"12","key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne T","year":"2017","unstructured":"Danne T, Nimri R, Battelino T International consensus on use of continuous glucose monitoring. Diabetes Care 40(12), 1631\u20131640 (2017).","journal-title":"Diabetes Care"},{"key":"e_1_3_10_26_2","volume-title":"The EQUATOR Network Reporting Guideline Platform","author":"von Elm E","year":"2025","unstructured":"von Elm E, Altman DG, Egger M The STROBE reporting checklist. In: The EQUATOR Network Reporting Guideline Platform. Harwood J, Albury C, de Beyer J, Schl\u00fcssel M, Collins G (Eds). The UK EQUATOR Centre (2025). https:\/\/resources.equator-network.org\/reporting-guidelines\/strobe\/strobe-checklist.docx"},{"key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"111093","DOI":"10.1016\/j.diabres.2024.111093","article-title":"Prevalence and associations of impaired awareness of hypoglycemia in a pediatric Type 1 diabetes population \u2013 The Norwegian Childhood Diabetes Registry","volume":"209","author":"Hatle H","year":"2024","unstructured":"Hatle H, Skrivarhaug T, Bj\u00f8rgaas MR, \u00c5svold BO, R\u00f8 TB. Prevalence and associations of impaired awareness of hypoglycemia in a pediatric Type 1 diabetes population \u2013 The Norwegian Childhood Diabetes Registry. Diabetes Res. Clin. Pract. 209, 111093 (2024).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"e_1_3_10_28_2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.pcl.2015.04.004","article-title":"Long-term outcomes in youths with diabetes mellitus","volume":"62","author":"White NH","year":"2015","unstructured":"White NH. Long-term outcomes in youths with diabetes mellitus. Pediatr. Clin. North Am. 62(4), 889\u2013909 (2015).","journal-title":"Pediatr. Clin. North Am."},{"issue":"1","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13098-023-01219-2","article-title":"Time in range and complications of diabetes: a cross-sectional analysis of patients with Type 1 diabetes","volume":"15","author":"Bezerra MF","year":"2023","unstructured":"Bezerra MF, Neves C, Neves JS, Carvalho D. Time in range and complications of diabetes: a cross-sectional analysis of patients with Type 1 diabetes. Diabetol. Metab. Syndr. 15(1), 244 (2023).","journal-title":"Diabetol. Metab. Syndr."},{"issue":"4","key":"e_1_3_10_30_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck RW","year":"2019","unstructured":"Beck RW, Bergenstal RM, Cheng P The relationships between time in range, hyperglycemia metrics, and HbA1c. J. Diabetes Sci. Technol. 13(4), 614\u2013626 (2019).","journal-title":"J. Diabetes Sci. Technol."},{"issue":"1","key":"e_1_3_10_31_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2337\/dci24-0058","article-title":"Using time in tight glucose range as a health-promoting strategy in preschoolers with Type 1 diabetes","volume":"48","author":"Sundberg F","year":"2024","unstructured":"Sundberg F, Smart CE, Samuelsson J, \u00c5kesson K, Krogvold L. Using time in tight glucose range as a health-promoting strategy in preschoolers with Type 1 diabetes. Diabetes Care 48(1), 6\u201314 (2024).","journal-title":"Diabetes Care"},{"issue":"7","key":"e_1_3_10_32_2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/dc16-1769","article-title":"Toward defining the threshold between low and high glucose variability in diabetes","volume":"40","author":"Monnier L","year":"2016","unstructured":"Monnier L, Colette C, Wojtusciszyn A Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 40(7), 832\u2013838 (2016).","journal-title":"Diabetes Care"},{"issue":"1","key":"e_1_3_10_33_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12902-023-01517-w","article-title":"Glycemic variability and time in range among children with Type 1 diabetes on insulin pump during the Covid-19 pandemic in Egypt; single center experience","volume":"23","author":"Maksoud AAA","year":"2023","unstructured":"Maksoud AAA, Salah NY, Ayoup SAA. Glycemic variability and time in range among children with Type 1 diabetes on insulin pump during the Covid-19 pandemic in Egypt; single center experience. BMC Endocr. Disord. 23(1), 262 (2023).","journal-title":"BMC Endocr. Disord."},{"issue":"3","key":"e_1_3_10_34_2","doi-asserted-by":"crossref","first-page":"e243474","DOI":"10.1001\/jamanetworkopen.2024.3474","article-title":"Estimated sustainable cost-based prices for diabetes medicines","volume":"7","author":"Barber MJ","year":"2024","unstructured":"Barber MJ, Gotham D, Bygrave H Estimated sustainable cost-based prices for diabetes medicines. JAMA Network Open 7(3), e243474 (2024).","journal-title":"JAMA Network Open"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:24:53Z","timestamp":1785507893000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.57264\/cer-2026-0036"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0036","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"e260036"}}